MODERNA US, INC.: $90.9M Department of Health and Human Services Contract Vehicle

The Department of Health and Human Services, through the Centers for Disease Control and Prevention, awarded Moderna US, Inc. a $90.9M indefinite delivery/indefinite quantity contract for pediatric COVID vaccines under Executive Order 14398. The contract covers the period from June 2026 to May 2027, ensuring a two-year supply of vaccines for children. Moderna, Inc. is the publicly traded parent company and direct recipient of this award.

For Moderna, this contract represents approximately 1.3% of its FY2025 annual revenue of $6.8B. While not transformative, it provides a stable revenue stream at a time when Moderna's overall sales have declined sharply from $19.3B in FY2024 to $6.8B in FY2025, and the company reported a net loss of $4.7B. The pediatric vaccine segment is a specific product line that helps maintain Moderna's government relationship and supports its vaccine manufacturing infrastructure.

No directly related legislation was identified among the provided bill signals. The contract appears to be an administrative renewal under existing pandemic preparedness authorities rather than a new legislative initiative. However, the continued government investment in COVID vaccines reflects ongoing public health priorities.

Supply chain beneficiaries include contract manufacturer Catalent, which produces Moderna's vaccines, and Thermo Fisher, which supplies raw materials and consumables. For Catalent, this contract could generate $5-15M in additional revenue, while for Thermo Fisher the impact is smaller given its diversified revenue base of over $40B.

Historically, government vaccine contracts provide predictable multi-year revenue for pharmaceutical companies. Moderna's stock has been volatile due to declining COVID vaccine sales, but this contract offers some near-term visibility. The pediatric focus also aligns with broader vaccination campaigns that tend to sustain demand.